A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy

NCT01859741 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

172

Enrollment

INDUSTRY

Sponsor class

Stopped OMP-59R5 did not improve PFS.

Conditions

Stage IV Small Cell Lung Cancer

Interventions

DRUG: OMP-59R5
DRUG: Etoposide
DRUG: Placebo
DRUG: Cisplatin or Carboplatin

Sponsor

OncoMed Pharmaceuticals, Inc.